Raze Therapeutics, a leading next-generation cancer metabolism company, announced today the addition of Robert Copeland, PhD, President of Research and Chief Scientific Officer at Epizyme, Inc., to its Scientific Advisory Board (SAB). Dr. Copeland brings deep experience in oncology drug discovery and development to Raze’s SAB.
